Hokkaido University · 의학
Akihiro Homma 교수의 연구실은 고역암성 비부비동 종양 및 헤드 앤 네이크 종양 치료를 중심으로, 국소 치료 전략의 혁신을 추구하고 있습니다. 특히 초고용량 시스플라틴을 이용한 동맥내 정맥주입 치료(초선택적 동맥화학요법)와 방사선 치료의 조합이 국소 진행성 암에서도 치유 가능성을 보여주며, 장기 보존 치료의 새로운 기준을 제시하고 있습니다. 이와 함께 주 1회 투여의 카보플라틴 투여법 등 치료의 내성과 편의성을 높이는 치료 루틴 개발에도 주력하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Although a single institution experience, the results of the current study suggest that RADPLAT can cure the majority of patients with advanced cancer of the nasal cavity and paranasal sinuses, as well as preserve organs. Late adverse reactions should be monitored in future studies.
Weekly cisplatin could be easier to manage than three-weekly cisplatin, because patients can be monitored more regularly for toxicity allowing the schedule to be altered if required. This regimen appears to be a suitable alternative to three-weekly high-dose cisplatin with concomitant radiotherapy.
UMIN-CTR (UMIN000032600), Clinicaltrials.gov (NCT03569436).
These findings suggest that weekly carboplatin treatment is preferable to daily low-dose cisplatin. This could be because the total dose of cisplatin was too low to be effective.
Intra-arterial chemotherapy has been used to treat localized malignant neoplasms in patients with head and neck cancer for over 50 years as the head and neck region is particularly well suited to regional chemotherapy. Early intra-arterial chemotherapy did not prove its efficacy. In addition, the additional complications associated with establishing and maintaining arterial access have further dampened enthusiasm for this approach. Subsequent significant advances in vascular radiology techniques
We confirmed the efficacy of superselective arterial infusion and concomitant radiotherapy, which can concentrate the attack of supradose cisplatin on locoregional disease. Even patients with unresectable disease can be cured. Further studies are needed to establish the indications, long-term outcome, and possible late side effects of this treatment.
